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Abstract
The immunomodulatory effects of photodynamic therapy (PDT) have been reported in several photosensitizers.
Pheophorbide a (Pa), a chlorophyll derivative, shows antitumor effects on a number of human cancers in a PDT
approach (Pa-PDT); however, the potential effect of Pa-PDT on the anticancer immunity has never been studied. In
the present work, the underlying action mechanism of Pa-PDT was systemically investigated with a human hepa-
toma cell line HepG2. We found that Pa-PDT significantly inhibited the growth of HepG2 cells with a half maximal
inhibitory concentration/endoplasmic reticulum of 0.35 μM at 24 hours by the induction of apoptosis, as shown by
externalization of phosphatidylserine, release of mitochondrial cytochrome c, and activation of the caspases cascade
in the treated cells. Interestingly, using two-dimensional polyacrylamide gel electrophoresis analysis, a 57-kDa dis-
ulfide-isomerase–like ER resident protein (ERp57) that belongs to the HLA class I–restricted antigen-processing
machinery was found to be mediated during the Pa-PDT treatment. This activation of antigen presentation was con-
firmed by Western blot analysis and immunostaining. Furthermore, a cross-presentation of antigen with HLA class I
proteins and 70-kDa heat shock protein was found in Pa-PDT–treated cells, as shown by the confocal microscopic
observation and immunoprecipitation assay. Nevertheless, the immunogenicity of HepG2 cells was increased by
Pa-PDT treatment that triggered phagocytic capture by human macrophages. Our findings provide the first evidence
that Pa-PDT can trigger both apoptosis and cancer immunity in the tumor host.
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Introduction
Photodynamic therapy (PDT) is a recently developed modality for
tumor treatment. It is currently used in the treatment of many can-
cers including lung cancer, head and neck cancers, liver metastases,
cholangiocarcinoma, and prostrate cancer [1]. This approach has also
been applied to treat various diseases, including psoriasis, rickets, vit-
iligo, and skin cancer by ancient Egyptian, Indian, and Chinese
thousands of year ago [2,3]. PDT requires the simultaneous presence
of photosensitizer and light, both are nontoxic individually, to induce
rapid cytotoxicity on the target tissue in the presence of oxygen
where the inhibitory effects of PDT can be achieved by inducing
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apoptosis [4,5]. Enhancement of systemic antitumor immunity is
another important strategy in cancer treatment. Recently, numerous
preclinical studies have found that local PDT treatment can enhance
anticancer immunity through the activation of neutrophils and nat-
ural killer cells [6,7] because of the induction of acute inflammation,
expression of heat shock proteins (HSPs), invasion, and infiltration of
the tumor by leukocytes, which might increase the presentation of
tumor-derived antigens to T cells [8].
Pheophorbide a (Pa), a derivative of chlorophyll a, is a breakdown
product during the turnover of chlorophyll a in plant cells [9]. Our
previous study has identified Pa as the active component in the anti-
proliferative effect of a traditional Chinese medicine Scutellaria barbata
on human hepatoma Hep3B cells [10]. It has also been reported as a
photocytotoxic component ofThunbergia laurifoliaLindl andAglaonema
simplex [11,12]. Pa generates singlet oxygen to trigger cancer cell death
during irradiation in the presence of oxygen. The effect of Pa-based
PDT (Pa-PDT) has been demonstrated on a number of human cancer
cells, including Jurkat leukemia, pigmented melanoma, colonic cancer,
and pancreatic carcinoma [13–16]. The efficacy of Pa-PDTon hepato-
cellular carcinoma has been evaluated in vivo, and its antitumor effect
has also been demonstrated in vitro on the hepatitis B virus–induced
human hepatoma cell line Hep3B as well as on the hepatitis C virus–
induced human hepatoma cell line with multidrug resistance property in
our previous studies, where the induction of mitochondrial-dependent
apoptosis is suggested to be a common pathway for Pa-PDTon human
hepatoma treatments [17–20].
The immunomodulatory effects of PDT, including both immuno-
stimulation and immunosuppression, have been reported in several
photosensitizers [3,6,7]. These phenomena may further enhance
the therapeutic efficiency on both primary and metastasis cancers
in antitumor PDT [21]. Pa is a well-studied second-generation photo-
sensitizer; however, its potential effects on immunity have not yet been
studied. Our present work was done with a proteomic approach to re-
veal the potential effect of Pa-PDT on cancer immunity by using the
human hepatoma cell line HepG2 as an in vitro model. The results
demonstrated that Pa-PDT triggered the antigen presentation together
with apoptosis in the treated HepG2 cells. This study provides the first
reference of the immunomodulatory effect of Pa-PDTon human can-
cer cells in vitro.
Materials and Methods
Materials
Culture media were purchased from Invitrogen (Carlsbad, CA). All
other chemicals were purchased from Sigma Chemical Co (St. Louis,
MO). Pa originally purified from S. barbata [10] is now commercially
available. Pa used in this study was purchased from Frontier Scientific
(Logan, UT).
Cell Cultures
Human hepatocellular carcinoma HepG2 cells (American Type
Culture Collection, ATCC, Manassas, VA) were cultured in RPMI
1640, and human normal hepatic cells WRL-68 (ATCC) were main-
tained in minimum essential medium. All media contained 10%
(vol./vol.) fetal bovine serum, 100 U/ml penicillin G, and 100 μg/ml
streptomycin. Sodium pyruvate (1 mM) was exclusively added into
the minimum essential medium. The cells were incubated at 37°C in
a humidified atmosphere of air/CO2 (95%:5%).
Irradiation of Photosensitizer
Cells were preloaded with Pa for 2 hours. After washings, the cells
were photoirradiated for 20 minutes using a 600-W quartz-halogen
lamp that is attenuated by a 10-cm layer of water and a long-pass
610-nm filter. The light intensity was 70 mW/cm2 (i.e., 20 minutes
of irradiation = 84 J/cm2) [17–19].
Effects of Pa-PDT on Cell Viability
Cells (1 × 104 per well) were seeded in a 96-well culture plate and
incubated for 24 hours to allow attachment. After washing with PBS,
the cells were incubated with the appropriate concentrations of Pa
followed by photoactivation. After 48 hours, the cells were washed
gently with phosphate-buffered saline (PBS). Thirty microliters of
methyl-thiazoldiphenyl tetrazolium (MTT) (5 mg/ml) was added to
each well and incubated for 2 hours at 37°C. Then, the MTT solution
was replaced by 100 μl of dimethyl sulfoxide in each well. Absorbance
was measured with a microtiter plate reader (Bio-Rad, Hercules, CA)
at 540 nm, and all data were calculated as percentage of control.
Measurement of Phosphatidylserine Translocation
HepG2 cells (3 × 105 per well) were seeded in a six-well culture plate
and collected 1 hour after the PDT treatment as described in our pre-
vious study [22]. The cells were stained with the annexin V–fluorescein
isothiocyanate (FITC) kit (Trevigen, Gaithersburg, MD) and analyzed
by FACSort flow cytometry (Becton Dickinson Bioscience Corp, San
Jose, CA) with the CellQuest software (BDBiosciences). The cell popu-
lation was gated by forward scatter and side scatter, and the fluorescence
signals were acquired by the FL1 and FL3 channels in log scale.
Western Blot Analysis
The method described previously was used [22,23]. The PDT-
treated cells (3 × 106 per dish) collected at 4 hours after PDTwere ex-
tractedwith the whole-cell extraction buffer (2% sodiumdodecyl sulfate
[SDS], 10% glycerol, 625 mM Tris-HCl [pH 6.8], β-mercaptoethanol
[5% vol./vol.]) and subjected to gel electrophoresis. The expressions of
target proteins were monitored with primary antibodies against β-actin
(1:5000), HLA class I (1:1000; Sigma), p53 (1:1000), procaspase-3
(1:1000), procaspase-8 (1:1000; Santa Cruz Biotechnology, Santa Cruz,
CA), procaspase-9 and caspase-9 (1:1000; Stressgen, Ann Arbor, MI),
ERp57 (1:1000), HSP70 (1:5000; Abcam, Cambridge, UK), and cal-
reticulin (CRT) (1:5000; Abcam). For the measurement of cytochrome
c release, the cytosolic protein was collected with the lysis buffer (75 mM
NaCl, 1 mMNaH2PO4, 8 mMNa2HPO4, 250 mM sucrose, 21 μg/ml
aprotinin, 5 μg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride,
and 25 μg digitonin), and the supernatant collected was used forWestern
blot analysis with primary antihuman cytochrome c antibody (1:1000;
Santa Cruz). The protein content of each sample was normalized by
the corresponding β-actin level. After incubating with the secondary anti-
body conjugated with horseradish peroxidase, the immunodetected pro-
teins were visualized by using an enhanced chemiluminescence assay kit
(Amersham Life Science, Pittsburgh, PA).
Two-dimensional Gel Electrophoretic Analysis
Cells (1 × 106) were seeded in a 100-mm culture dish and incu-
bated for 24 hours to allow attachment. Four hours after 0.4 μM Pa
without PDT (control) or 0.4 μM Pa-PDT treatment, the cells were
collected and washed five times with cell washing buffer (10 mM
Tris-base, 250 mM sucrose, pH 7.4). The cells were lysed in the lysis
buffer (8 M urea, 4% CHAPS, 2% pharmalyte 3-10), and 150 μg of
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protein of the collected supernatant was subjected to first-dimension
isoelectric focusing with a 13-cm immobilized pH gradient (pH)
strip (pH 3-10 Immobiline DryStrip; Amersham Biosciences, Pitts-
burgh, PA) by using the Ettan IPGphor Isoelectric Focusing Unit
(Amersham Biosciences) with the following profile: 30 V for 10 hours
(gradient), 200 V for 1 hour (step-and-hold), 500 V for 1 hour (step-
and-hold), 8000 V for 30 minutes (gradient), 8000 V for 6.5 hours
(step-and-hold) until a total of 60,000 V-h had been achieved. The
IPG strips were then subjected to the second-dimension electrophoretic
analysis with a 10% SDS polyacrylamide gel electrophoresis (two-
dimensional SDS-PAGE) by using the SE 600 Ruby Electrophoresis
Unit (Amersham Biosciences) at a constant 150 V, and the collected
gel was finally stained by using PlusOne Silver Staining Kit (Amersham
Biosciences). The results were analyzed by the software Image Master
2D version 2.0 (Amersham Biosciences). The mediated protein spots
were excised from the gel and finally identified by Matrix assisted laser
Figure 1. Activation of mitochondrial-mediated apoptosis in Pa-PDT treated HepG2 cells. (A) In vitro inhibitory effect of Pa-PDT in HepG2
and WRL-68 cells. The cells (1 × 104 per well) were preincubated with Pa in a 96-well plate for 2 hours and then received light illumi-
nation (84 J/cm2) for 20 minutes. In the control group, Pa-treated HepG2 cells received no light illumination. Cell survival was assessed
by MTT assay 24 hours after treatment. Results are mean ± SD of three independent experiments. (B) Externalization of PS in Pa-PDT–
treated cells. The cells were collected at 1 hour after treatment and stained with the annexin V–FITC and PI costaining kit. The cells were
submitted to flow cytometry, where the percentages of cell population in each quadrant were shown as mean in the figures of five
independent experiments. (C) Change in the expression level of apoptotic proteins in Pa-PDT–treated HepG2 cells. Cells (3 × 106) were
treated with solvent (0.04% ethanol [CTL]) or Pa (0.4 and 0.6 μM) for 2 hours and then with light illumination (84 J/cm2) for 20 minutes.
Twenty-four hours after treatment, the whole-cell lysates were prepared, and the change in the level of various apoptosis-related
proteins was analyzed using Western blot analysis. For the release of mitochondrial cytochrome c, the cytosolic protein was collected
1 hour after treatment. The housekeeping protein β-actin was also probed for normalization. Data shown are representative of five
independent experiments.
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desorption-ionization time-of-flight mass spectrometry (MALDI-TOF
MS) [24].
Immunohistochemistry
Cells (3 × 105 per well) were grown on the coverslips. The PDT-
treated cells were fixed with chilled fixation buffer (70% methanol
and 30% ethanol) at −20°C for 20 minutes and then blocked with
TBS with 0.1% of Tween 20 that contains 10% fetal bovine serum at
4°C for 30 minutes as described in our previous study [18]. The fixed
samples were incubated overnight at 4°C with monoclonal anti–HLA
class I antibody (1:500; Sigma), or rabbit anti–HLA class I and
mouse anti-HSP70 antibodies (Abcam) and then incubated with
FITC-conjugated goat antimouse immunoglobulin G or both with
R-phycoerythrin–conjugated antirabbit (1:500; Zymed, South San
Francisco, CA) antibodies for a further 2 hours. Finally, the samples
were washed three times with TBS with 0.1% of Tween 20 and ob-
served under a Nikon TE2000 fluorescence microscope (Nikon,
Badhoevedrop, The Netherlands) with an excitation wavelength at
490 nm and an emission wavelength at 516 nm or were viewed under
a Leica SP5 confocal microscope (Leica,Wetzlar, Germany) where Alexa
Fluor 594 and FITC fluorescence was detected by using appropriate
excitation (490 and 578 nm) and emission (516 and 610 nm) wave-
lengths. HLA class I proteins were assigned as red, and HSP70 proteins
were shown in green. Images were merged together by using the Meta-
Morph software (Universal Imaging Corp, Downingtown, PA).
Immunoprecipitation
The PDT-treated cells (3 × 106 per dish) collected at 4 hours after
PDTwere lysed by incubating in 1 ml of nondenaturing lysis buffer
(20 mM Tris-HCl, pH 8, 137 mM NaCl, 10% glycerol, 1% Triton
X-100, 2 mM EDTA, and 20 μg/ml aprotinin) for 30 minutes at 4°C.
The supernatant was collected after centrifuging for 20 minutes at
12,000g. The collected cell lysate (200 μg) was incubated with anti–
HLA class I antibody (Abcam) at 4°C overnight, and then 70 μl of pre-
swollen protein-A–conjugated beads was added into the sample and
incubated for 4 hours. After removing the supernatant and washing
with lysis buffer three times, 25 μl of whole-cell extraction buffer
was added to denature the protein and separate it from the protein-A
beads. The samples were eventually analyzed byWestern blot assay with
anti-HSP70 antibody to study the interaction between HSP70 and
HLA class I proteins.
Phagocytic Activity Assays of Human Macrophage
Fresh human buffy coat obtained from healthy volunteers of Hong
Kong Red Cross Blood Transfusion Service was diluted two-fold with
PBS at 4°C and centrifuged using an isotonic Percoll solution (den-
sity 1.082 g/ml; Amersham and Pharmacia Biotech, Uppsala, Sweden)
for 30minutes at 1000gwithout deceleration. After centrifugation, four
layers of fluids appeared in the column. The thin white interface be-
tween the top and third layers containing the viable peripheral blood
mononuclear cells including lymphocytes andmonocytes was collected.
The collected peripheral blood mononuclear cells were cultured with
RPMI for 2 hours, and the adherent cells in the culture flask were used
as human macrophages [25]. The phagocytosis of human macrophages
was evaluated using a commercial kit (Vybrant Phagocytosis Assay Kit;
Invitrogen). The intensities of fluorescence were acquired by a FLUO-
star Galaxy plate reader (BMG Labtech, Offenburg, Germany).
Figure 2. Protein expression profile of Pa-PDT–treated HepG2
cells. The total proteins of (A) 0.4 μM Pa (dark control) and (B)
0.4 μMPa-PDT–treated HepG2 cells were extracted at 4 hours after
illumination. The protein samples were subjected to isoelectric
focusing, then separated on a 10% SDS-PAGE gel, and finally visu-
alized by silver staining. The gel result was analyzed by the soft-
ware Image Master. (C) Enlarged regions showing the positions
and identities of the differentially expressed proteins MTHSP75
and ER60 in HepG2 cells after Pa-PDT treatment. The figure is a
representative of five trials.
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Statistical Analysis
Data were presented as mean ± SD of various numbers of experi-
ments. Statistical analysis was performed by one-way analysis of variance
with Bonferroni post hoc test (two-tailed). P < .05 was considered statis-
tically significant.
Results
Cytotoxicity of Pa-PDT on Human Hepatoma HepG2 Cells
and Normal Human Hepatic WRL-68 Cells
The antitumor effect of Pa-PDT was examined on the human
hepatocellular carcinoma cell line HepG2. A dose-dependent growth
inhibitory effect was shown on HepG2 cells with a half maximal in-
hibitory concentration (IC50) of 0.35 μMat 24 hours (Figure 1A). The
normal human hepatic cells WRL-68 were much more resistant to the
Pa-PDT effect: the cell viability was approximately 74% at a drug con-
centration of 1.0 μM (Figure 1A), and this result is consistent to that of
our previous study [18].
Activation of Intrinsic Apoptotic Pathway in Pa-PDT–Treated
HepG2 Cells
Translocation of membrane protein phosphatidylserine (PS) is a hall-
mark of apoptotic cells, and this phenomenon was observed on the Pa-
PDT–treated HepG2 cells in a dose-dependent manner. As shown in
Figure 1B, 31.4% and 54.9% of early apoptotic cells (annexin V–FITC–
positive and propidium iodide–negative) were found in HepG2 cells
after treating with 0.4 and 0.6 μM Pa-PDT, respectively, but only
4.5% in the control sample. For late apoptotic cells (annexin V–FITC–
positive and propidium iodide–positive), the percentage of cell popu-
lation was more than 30% in samples treated with 0.4 or 0.6 μM
Pa-PDT, whereas only 9.2% appeared as late apoptotic cells in the control
(Figure 1B). In addition, as shown in Figure 1C , cytochrome c in the
cytosolic fraction was significantly increased, implying a release of mito-
chondrial cytochrome c in the Pa-PDT–treated cells. Nevertheless, the
levels of procaspase-3 and -9 were decreased with inductions of p53
and caspase-9 expression, whereas the level of procaspase-8, responsible
for the extrinsic apoptotic pathway, was relatively unchanged after 0.4
and 0.6 μM Pa-PDT (Figure 1C ). Our findings confirmed that Pa-
PDT induced apoptosis in HepG2 cells through the mitochondria-
mediated pathway.
Identification of Pa-PDT–Mediated Protein Expression in
HepG2 Cells
To find out pathways that are potentially mediated by Pa-PDT,
protein lysate of Pa alone (dark control) and Pa-PDT–treated HepG2
cells were analyzed by two-dimensional PAGE, and the induced protein
spots were detected by the PDQuest software (Bio-Rad). Fifty-one
protein spots exhibited significantly different expression levels in the
Table 1. The Differentially Expressed Proteins Mediated by Pa-PDT Treatment in HepG2 Cells.
Protein Name MW (kDa) PI Protein Score CI (%)
Upregulated
Chaperonin 61.016 5.70 205 100.00
Heat shock 70-kDa protein 9B, precursor (MTHSP75) 73.734 5.97 179 100.00
Chain A, heat shock 70-kDa protein 42-kDa ATPase N-terminal domain (HSP70) 41.802 6.69 170 100.00
Prohibitin 29.786 5.57 161 100.00
HnRNP protein A2 35.984 8.67 92 100.00
Unnamed protein product (gi 10436678) 30.143 9.23 91 99.99
LEKTI precursor 120.693 8.39 90 99.99
CTCL tumor antigen se2-1 93.443 5.37 83 99.96
KIAA1640 protein 108.677 6.33 79 99.89
Myosin heavy chain, skeletal muscle, fetal (myosin heavy chain Iib) 222.874 5.67 72 99.39
Zinc finger protein 2 72.326 8.99 72 99.48
30S ribosomal protein S7 homolog 28.144 10.00 72 99.46
Disulfide isomerase ER 60 (ERp57) 56.748 5.88 71 99.30
Serine protease inhibitor Kazal-type 5 precursor 120.681 8.50 68 98.73
Bone marrow zinc finger protein 2 72.113 9.02 67 98.36
Zinc finger protein 311 69.930 9.16 66 98.03
DNA-binding protein 179.967 9.32 66 97.89
Tumor necrosis factor type 2 receptor–associated protein 55.758 8.19 60 90.55
Downregulated
Heat shock 70-kDa protein 8 isoform 2 53.484 5.62 186 100.00
Enolase 1 (alpha) protein (ENO1) 47.139 7.01 165 100.00
Phospholipase C-alpha 56.666 6.23 149 100.00
Protein disulfide isomerase–associated 3 precursor (ER-60) 56.740 5.88 142 100.00
Desmoplakin (DP) 331.570 6.44 103 100.00
Pyruvate kinase (EC 2.7.1.40) 57.966 7.20 103 100.00
Adenylate kinase 3 25.252 8.47 97 100.00
Triosephosphate isomerase (TIM) 26.609 7.10 96 100.00
Myosin heavy chain (MyHC-Iib) 222.000 5.67 92 100.00
Stress-induced phosphoprotein 1 (HSP70/HSP90-organizing protein) 62.599 6.40 92 100.00
Plectin 64.921 5.38 88 99.00
Tropomyosin isoform 28.938 4.79 83 99.96
Mitosin 357.063 5.06 72 99.47
Desmoplakin (DP) 33.200 6.44 68 98.67
KIAA1081 protein 115.038 5.96 66 97.93
WW domain binding protein 5 12.741 5.35 62 94.31
Cytosolic thyroid hormone-binding protein 57.964 7.95 62 94.44
The Pa-PDT–regulated proteins identified from two-dimensional gel electrophoresis and MALDI-TOF MS analysis were listed according to their protein scores (significant when >59) and confidence
interval (CI).
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0.4 μM Pa-PDT–treated sample (Figure 2B) when compared with the
dark control (0.4 μM Pa with PDT; Figure 2A). Among them, 35 pro-
tein spots were successfully identified by MALDI-TOF MS analysis.
Eighteen of them were upregulated, whereas 17 were downregulated
after the Pa-PDT treatment (Table 1). The expression changes of an
identified upregulated spot heat shock 70 kDa protein 9B precursor
(MTHSP75) and an identified downregulated spot protein disulfide
isomerase-associated 3 precursor (ER60) were illustrated in Figure 2C .
Induction of Antigen-Processing Machinery in
Pa-PDT–Treated HepG2 Cells
The activation of the antigen presentation machinery, in which
MTHSP75 and ER60 are involved [26], in Pa-PDT–treated HepG2
cells was further confirmed by Western blot analysis. As shown in Fig-
ure 3A, both HSP70, the active form of MTHSP75, and ERp57, the
cleavage form of ER60 protein, were increased in a dose-dependentman-
ner. The levels ofHLAclass I andCRT, proteins for the ERp57-mediated
antigen processing machinery, were also increased in a dose-dependent
manner after Pa-PDT treatment. The increase in the expression of
HLA class I protein was also obvious under a fluorescent microscope,
which showed a plasma membrane localization (Figure 3B). The
immunogenicity of Pa-PDT–treated cells was evaluated by coincubation
with human macrophages.
Involvement of HSP70 in HLA Class I–Mediated Antigen
Presentation during Pa-PDT
The involvement of HSP70 on antigen presentation is still contro-
versial. The potential interaction of HSP70 with HLA class I protein
was investigated in the present study. Subcellular localization of HLA
class I protein and HSP70 was revealed by immunostaining. Using
confocal microscope, the fluorescence of HSP70 and HLA class I
protein was concentrated on the plasma membrane (Figure 4A),
and these images overlapped well with each other (Figure 4B). The
interaction of HSP70 and HLA class I protein was further confirmed
by an immunoprecipitation method. HSP70 was detected in immune
complexes precipitated with antibody specific for HLA class I from
Figure 3. Induction of antigen presentation by Pa-PDT treatment. (A) Change in the expression level of proteins related to antigen
presentation machinery in Pa-PDT–treated HepG2 cells. Cells (3 × 106) were treated with solvent (0.04% ethanol [CTL]) or Pa (0.4 and
0.6 μM) for 2 hours and then with light illumination (84 J/cm2) for 20 minutes. Four hours after treatment, the whole-cell lysates were
prepared, and the expression levels of various related proteins were analyzed using Western blot. The housekeeping protein β-actin was
also probed for normalization. Data shown are representative of five independent experiments. (B) The induction of HLA class I protein
expression in Pa-PDT–treated HepG2 cells. The Pa-PDT–treated cells (5 × 104 per well) were fixed at 24 hours after treatment and over-
night immunostained with monoclonal anti–HLA class I antibody. The stained cells were probed with FITC-conjugated secondary anti-
body for 2 hours before observation under a Nikon TE2000 fluorescence microscope. Fluorescence micrographs were acquired with an
excitation wavelength at 400 to 440 nm and an emission wavelength at 590 to 650 nm. The images are representatives of three inde-
pendent trials. Bar, 20 μm.
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Pa-PDT–treated HepG2 cells lysate (Figure 4C ). Our data suggested
that HSP70 was recruited by HLA class I protein during Pa-PDT treat-
ment in HepG2 cells.
Induction of Phagocytic Activity of Human Macrophages by
Pa-PDT–Treated HepG2 Cells
In addition, the effect of Pa-PDT treatment on immunogenicity of
human cancer cells was investigated in this study. As shown in Fig-
ure 5, the phagocytic activity of the macrophages was increased by
approximately two-fold with the addition of Pa-PDT treated HepG2
cells. Interestingly, the phagocytic activity was significantly decreased
to 27.1% in the sample where HepG2 cells were treated with solvent
only (P < .05). Our study therefore demonstrated that Pa-PDT treat-
ment would also give a positive influence on the phagocytic capture
and ingestion of human hepatoma HepG2 cells by macrophages.
Discussion
Pa is a well-studied second-generation photosensitizer that establishes
its antitumor effects on cancer cells through apoptosis induction
[17–20]. The inhibitory effect of Pa-PDT was specifically shown
on human hepatoma cells in this study. Pa-PDTacted on HepG2 cells
with the IC50 value of 0.35 μM at 24 hours, whereas 73.9% and
91.4% cell survival rates were found in the human normal hepatic cells
WRL-68 treated with 1.0 μM Pa-PDTand HepG2 cells with 1.0 μM
Pa treatment alone (without light illumination), respectively
(Figure 1A). Conversely, a commercial photosensitizer zinc (II) phthalo-
cyanine had higher cytotoxicity in PDTonWRL-68 than HepG2 cells,
the IC50 values being 0.7 and 1.3 μM, respectively, at 24 hours (data not
shown). The difference in the cytotoxicity of Pa-PDT and zinc (II)
phthalocyanine in human hepatoma and normal hepatic cells might
be related to the subcellular localization of the photosensitizers. Zinc
(II) phthalocyanine was found in Golgi apparatus [27], but Pa was
concentrated in mitochondria [17,18]. In addition, Pa was reported
to have an additionalmode of protection by increasing the detoxification
glutathione-S -transferase gene expression on normal liver cells, thus
making Pa-PDT less cytotoxic on WRL-68 cells [28]. Furthermore, a
similar phenomenon was suggested by Evrard et al. [29] that Pa-PDT
showed selective cytotoxicity on the pancreatic rat carcinoma with an
in vivomodel study. Mechanistic study of Pa-PDT–mediated cell death
on HepG2 cells was carried out in the present study. The hallmark
Figure 4. Association of HSP70 with HLA class I protein in Pa-PDT–treated HepG2 cells. (A) Intracellular tracking of fluorescence-labeled
HSP70 and HLA class I proteins using confocal microscopy. HepG2 cells were treated with 0.6 μM Pa-PDT, fixed at 24 hours after
illumination, and overnight immunostained with monoclonal anti-HSP70 and anti-HLA class I antibodies. The stained cells were then
further probed with secondary antibody that is either FITC- or Alexa Fluor 594–conjugated for 2 hours before observation. Fluorescence
micrographs were acquired with a Leica SP5 confocal microscope, where HSP70 was assigned as green (left panel with a scale bar =
20 μm), and the HLA class I protein was assigned as red (middle panel). In the merged image, colocalization of HSP70 and HLA class I
protein showed yellow color (right panel). (B) Quantification of protein colocalization. Confocal merged images (right panel) and fluo-
rescence topographic profiles (left panel) of Pa-PDT–treated HepG2 cells costained with anti-HSP and anti–HLA class I protein antibodies
were shown. The green rod (ROM) indicates the analyzed longitudinal transcellular zone. (C) Coimmunoprecipitation of HLA class I
interacting proteins in Pa-PDT–treated HepG2 cells. The samples CTL (solvent control) and 0.6 μM Pa-PDT–treated HepG2 cells (Pa-
PDT) were collected at 4 hours after PDT treatment and immunoprecipitated with anti–HLA class I antibodies, and the total HepG2 cell
lysate were collected without the immunoprecipitation step and used as a positive control for the anti–HSP70 antibody (Total Cell Ly-
sate) followed by SDS-PAGE and immunoblot analysis with anti–HSP70 antibodies. Data are representative of three independent trials.
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phenomenon of apoptosis, PS externalization, was found (Figure 1B),
and the mitochondrial-mediated apoptotic pathway was shown to be
activated (Figure 1C ) in the Pa-PDT–treated sample. Our results sug-
gested that Pa-PDT induced cancer cell death mainly by induction of
apoptosis through the intrinsic apoptotic pathway in HepG2 cells as it
does in other cancer cells [13–20]. Pa-PDT has a significant therapeutic
potential and it could possess selectivity for human hepatoma cells.
The importance of immune system in PDT on cancer treatment
has been raised recently. Spontaneous regression in advanced tumors
including hepatocellular carcinoma has been reported and the signif-
icances of PDT on immunostimulation or immunosuppression have
been well documented [30–33]. It inspires an ideal cancer therapy
that can give direct cytotoxicity to the tumor cells and trigger the
immune reorganization of cancer cells at the same time. So, the ther-
apeutic potential of Pa-PDT on cancer immunity was investigated in
this study. Protein expression profile of Pa-PDT–treated HepG2 cells
was analyzed by using two-dimensional PAGE (Figure 2, A and B);
the identified Pa-PDT–regulated proteins were classified according to
several functional categories, including antigen presentation (e.g.,
ER60), HSP (e.g., chaperonin, MTHSP75), cell death pathway (e.g.,
tumor necrosis factor type 2 receptor–associated protein) as well as
those with unknown function (Table 1). The identified proteins
MTHSP75 and ER60 with high protein scores in the MALDI-TOF
MS analysis were chosen for further study (Figure 2C).
Protein MTHSP75 is the precursor of HSP70. In situ HSP70
overexpression is known to enhance DC antigen presentation and
overcome host immune tolerance to tumor antigens. It is involved
in antigen presentation and antitumor immune responses by coop-
erating with the antigen presentation cells [34,35]. ER60 is the pre-
cursor of protein disulfide isomerase ERp57 that functions together
with calnexin, CRT, and tapasin as a molecular chaperone in glyco-
protein biosynthesis, including the generation of a stable HLA class
I–peptide complex in the ER [36,37]. Our results demonstrated that
the activation of ERp57-mediated pathway occurred during Pa-PDT
treatment where the HLA class I–restricted antigen presentation
machinery was triggered and the expression of HLA class I protein
was upregulated on the plasma membrane of the treated HepG2 cells
(Figure 3, A and B ). Our findings suggest that Pa-PDT can trigger
antigen presentation in the treated cancer cells to stimulate the host
immune response.
Furthermore, the Pa-PDT–triggered antigen presentation was
found to work together with HSP70 (Figure 4, A and B) in the treated
HepG2 cells. The interaction of HSP70 and HLA class I protein was
confirmed by the coimmunoprecipitation assay (Figure 4C ). Recently,
HSP70 is suggested to be involved in antigen presentation during PDT
treatments. It forms stable complexes, cross-presents the tumor antigens
with HLA proteins, resulting in an antigen-specific T-cell stimulation in
the cancer host [35,38,39]. Nevertheless, there is a new approach for
developing tumor vaccines by using PDT-treated cancer cell lysates,
and Pa-PDT should be considered as one of the candidates [40]. Our
results supported that HSP70 was upregulated and collaborated with
the HLA class I proteins to enhance the antigen presentation efficiency
in the Pa-PDT–treated cells.
Nevertheless, the effect of Pa-PDT–induced immunogenicity of
human liver cancer cells was also demonstrated with primary human
macrophages; as shown in Figure 5, a significant increase of phago-
cytic activity was found when the macrophages were coincubated
with Pa-PDT–treated HepG2 cells. Interestingly, an inhibitory effect
was given to the human macrophages when the HepG2 cells (dark
control) were applied instead (Figure 5). Our finding is consisting to
the discovery by Korbelik and Krosl’s [41] work, where the PDT-
treated cancer cells could enhance macrophage cytotoxicity.
Conclusions
Taken together, our findings provide the first evidence that Pa-PDT
would activate the HLA class I–restricted antigen presentation machin-
ery in HepG2 cells and result in an enhancement of anticancer immu-
nity in the tumor host that would enhance the efficiency of anticancer
treatment with Pa-PDT.
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